Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma

Abstract Background Immunotherapies targeting PD-1 and CTLA-4 are key components of the treatment of metastatic clear cell renal cell carcinoma (mccRCC). However, they have distinct safety profiles and resistance to treatment can occur. We assess soluble TIM-3 (sTIM-3) in the plasma of mccRCC patien...

Cijeli opis

Bibliografski detalji

Glavni autori:	Ivan Pourmir, Nadine Benhamouda, Thi Tran, Hugo Roux, Joséphine Pineau, Alain Gey, Andyara Munoz, Nesrine Mabrouk, Nicolas Epaillard, Virginie Verkarre, Yann-Alexandre Vano, Eric Tartour, Stéphane Oudard
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2025-02-01
Serija:	Journal of Experimental & Clinical Cancer Research
Teme:	Clear cell renal cell carcinoma Soluble TIM-3 Myeloid cells Biomarkers Immunotherapy Immune checkpoints
Online pristup:	https://doi.org/10.1186/s13046-025-03293-y
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!